PLoS ONE,
Journal Year:
2023,
Volume and Issue:
18(12), P. e0293046 - e0293046
Published: Dec. 1, 2023
Human
adenovirus
(HAdV),
particularly
the
HAdV
type
5
(HAdV-5),
has
been
extensively
utilized
in
development
of
vector
vaccines
due
to
its
high
immunogenicity,
good
safety
profile,
and
ease
propagation.
However,
one
main
challenges
use
is
presence
pre-existing
immunity
among
vaccine
recipients.
Pre-existing
neutralizing
antibodies
(NAbs)
can
prevent
uptake
HAdV-5
vectors
reduce
efficacy.
Hence,
this
study
investigated
seroprevalence
NAbs
against
urban
rural
regions
Philippines.
Luciferase-based
neutralization
assay
was
performed
on
391
plasma/serum
samples.
Out
these
samples,
346
or
88.5%
were
positive
for
NAbs,
majority
them
(56.8%)
had
titers
virus.
Among
included
study,
Bicol
(Region
V)
highest
rate
(94.1%).
Our
findings
show
that
a
significant
number
adults
Philippines
have
HAdV-5.
This
supports
recommendation
vaccination
programs
country
should
consider
implementing
techniques,
such
as
prime-boost
regimen
addition
booster
doses,
address
potential
negative
effects
efficacy
adenoviral
vector-based
vaccines.
ACS Omega,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Feb. 5, 2024
In
the
realm
of
cancer
immunotherapy,
a
profound
evolution
has
ushered
in
sophisticated
strategies
that
encompass
both
traditional
vaccines
and
emerging
viral
vaccines.
This
comprehensive
Review
offers
an
in-depth
exploration
methodologies,
clinical
applications,
success
stories,
future
prospects
these
approaches.
Traditional
have
undergone
significant
advancements
utilizing
diverse
modalities
such
as
proteins,
peptides,
dendritic
cells.
More
recent
innovations
focused
on
physiological
mechanisms
enabling
human
body
to
recognize
combat
precancerous
malignant
cells,
introducing
specific
markers
like
peptide-based
anticancer
targeting
tumor-associated
antigens.
Moreover,
vaccines,
leveraging
engineered
viruses
stimulate
immune
responses
against
antigens,
exhibit
substantial
promise
inducing
robust
enduring
immunity.
Integration
with
complementary
therapeutic
methods,
including
monoclonal
antibodies,
adjuvants,
radiation
therapy,
not
only
improved
survival
rates
but
also
deepened
our
understanding
virulence.
Recent
strides
vaccine
design,
encompassing
oncolytic
viruses,
virus-like
particles,
vectors,
mark
frontier
innovation.
While
advances
hold
immense
potential,
critical
challenges
must
be
addressed,
for
evasion,
potential
off-target
effects,
optimization
genomes.
landscape
noteworthy
take
spotlight
from
use
immunomodulatory
agents
enhancement
innate
adaptive
collaboration.
The
emergence
proteolysis-targeting
chimeras
(PROTACs)
precision
tools
therapy
is
particularly
exciting.
With
focus
various
cancers,
melanoma
formidable
solid
tumors,
this
critically
assesses
types
mechanisms,
barriers
efficacy,
safety
profiles,
immune-related
adverse
events,
providing
nuanced
perspective
underlying
involving
cytotoxic
T
natural
killer
underscores
transformative
cutting-edge
technologies
studies,
molecular
sequencing,
artificial
intelligence
advancing
field
These
expedite
progress
emphasize
multidimensional
rapidly
evolving
nature
research,
affirming
its
significance
broader
context
therapy.
Viruses,
Journal Year:
2023,
Volume and Issue:
15(12), P. 2378 - 2378
Published: Dec. 3, 2023
Efficient
and
targeted
delivery
of
a
DNA
payload
is
vital
for
developing
safe
gene
therapy.
Owing
to
the
recent
success
commercial
oncolytic
vector
multiple
COVID-19
vaccines,
adenovirus
vectors
are
back
in
spotlight.
Adenovirus
can
be
used
therapy
by
altering
wild-type
virus
making
it
replication-defective;
specific
viral
genes
removed
replaced
with
segment
that
holds
therapeutic
gene,
this
as
vehicle
tissue
delivery.
Modified
conditionally
replicative–oncolytic
adenoviruses
target
tumors
exclusively
have
been
studied
clinical
trials
extensively.
This
comprehensive
review
seeks
offer
summary
vectors,
exploring
their
characteristics,
genetic
enhancements,
diverse
applications
preclinical
settings.
A
significant
emphasis
placed
on
crucial
role
advancing
cancer
latest
breakthroughs
vaccine
various
diseases.
Additionally,
we
tackle
current
challenges
future
avenues
optimizing
promising
open
new
frontiers
fields
cell
therapies.
Current Issues in Molecular Biology,
Journal Year:
2024,
Volume and Issue:
46(3), P. 1904 - 1920
Published: Feb. 29, 2024
The
SARS-CoV-2
(Severe
Acute
Respiratory
Syndrome
Coronavirus-2)
virus
and
the
resulting
COVID-19
pandemic
have
had
devastating
lasting
impact
on
global
population.
Although
main
target
of
disease
is
respiratory
tract,
clinical
outcomes,
research
also
shown
significant
effects
infection
other
organ
systems.
Of
interest
in
this
review
effect
cardiovascular
system.
Complications,
including
hyperinflammatory
syndrome,
myocarditis,
cardiac
failure,
been
documented
context
infection.
These
complications
ultimately
contribute
to
worse
patient
especially
patients
with
pre-existing
conditions
such
as
hypertension,
diabetes,
or
(CVD).
Importantly
interestingly,
reports
demonstrated
that
causes
myocardial
injury
adults
without
contributes
systemic
pediatric
populations,
development
multisystem
inflammatory
syndrome
children
(MIS-C).
there
still
a
debate
over
exact
mechanisms
by
which
arise,
understanding
potential
paths
can
influence
system
create
an
environment
may
clarify
how
interacts
human
physiology.
In
addition
describing
propagation
presentation,
discusses
diagnostic
findings
treatment
strategies
evolution
management
for
presenting
complications,
focusing
prevention.
Applied Microbiology and Biotechnology,
Journal Year:
2024,
Volume and Issue:
108(1)
Published: Jan. 27, 2024
Abstract
Several
COVID-19
vaccines
use
adenovirus
vectors
to
deliver
the
SARS-CoV-2
spike
(S)
protein.
Immunization
with
these
promotes
immunity
against
S
protein,
but
also
itself.
This
could
interfere
entry
of
vaccine
into
cell,
reducing
its
efficacy.
Herein,
we
evaluate
efficiency
an
adenovirus-vectored
(chimpanzee
ChAdOx1
adenovirus,
AZD1222)
in
boosting
specific
compared
that
induced
by
a
recombinant
receptor-binding
domain
(RBD)-based
without
viral
vector.
Mice
immunized
AZD1222
human
were
given
booster
6
months
later,
either
homologous
or
based
on
RBD
delta
variant,
which
was
prevalent
at
start
this
study.
A
significant
increase
anti-RBD
antibody
levels
observed
rRBD-boosted
mice
(31–61%)
those
receiving
two
doses
(0%).
Significantly
higher
rates
PepMix™-
RBD-elicited
proliferation
IFNγ-producing
CD4
and
CD8
cells
from
boosted
one
RBD,
respectively.
The
lower
ChAdOx1-S
be
result
pre-existing
anti-vector
immunity,
increased
anti-adenovirus
antibodies
found
both
humans.
Taken
together,
results
point
importance
avoiding
recurrent
same
vector
individuals
memory
them.
It
illustrates
disadvantages
respect
protein
vaccines,
can
used
restriction
vaccine-booster
programs.
Key
points
•
(AZD1222)
may
not
effective
anti-SARS-CoV-2
is
Antibodies
elicited
rRBD-delta
persisted
for
up
3
ACS Applied Bio Materials,
Journal Year:
2024,
Volume and Issue:
7(8), P. 5037 - 5056
Published: May 24, 2024
The
oral
and
nasal
cavities
serve
as
critical
gateways
for
infectious
pathogens,
with
microorganisms
primarily
gaining
entry
through
these
routes.
Our
first
line
of
defense
against
invaders
is
the
mucosal
membrane,
a
protective
barrier
that
shields
body's
internal
systems
from
infection
while
also
contributing
to
vital
functions
like
air
nutrient
intake.
One
key
features
this
its
ability
protect
physiological
system
pathogens.
Additionally,
tolerance
plays
crucial
role
in
maintaining
homeostasis
by
regulating
pH
water
balance
within
body.
Recognizing
importance
barrier,
researchers
have
developed
various
formulations
enhance
immune
response.
Mucosal
vaccines,
example,
deliver
antigens
directly
tissues,
triggering
local
stimulation
ultimately
inducing
systemic
immunity.
Studies
shown
lipid-based
such
liposomes
virosomes
can
effectively
elicit
both
responses.
Furthermore,
mucoadhesive
polymeric
particles,
their
prolonged
delivery
target
sites,
demonstrated
an
enhanced
This
Review
delves
into
material
selection
approaches
optimizing
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(7), P. 795 - 795
Published: July 18, 2024
Immunity
against
respiratory
pathogens
is
often
short-term,
and,
consequently,
there
an
unmet
need
for
the
effective
prevention
of
such
infections.
One
infectious
disease
coronavirus
19
(COVID-19),
which
caused
by
novel
Beta
SARS-CoV-2
that
emerged
around
end
2019.
The
World
Health
Organization
declared
illness
a
pandemic
on
11
March
2020,
and
since
then
it
has
killed
or
sickened
millions
people
globally.
development
COVID-19
systemic
vaccines,
impressively
led
to
significant
reduction
in
severity,
hospitalization,
mortality,
contained
pandemic’s
expansion.
However,
these
vaccines
have
not
been
able
stop
virus
from
spreading
because
restricted
mucosal
immunity.
As
result,
breakthrough
infections
frequently
occurred,
new
strains
emerging.
Furthermore,
will
likely
continue
circulate
like
influenza
virus,
co-exist
with
humans.
upper
tract
nasal
cavity
are
primary
sites
infection
thus,
mucosal/nasal
vaccination
induce
response
virus’
transmission
warranted.
In
this
review,
we
present
status
both
approved
those
under
evaluation
clinical
trials.
our
approach
B-cell
peptide-based
applied
prime-boost
schedule
elicit
